CHRM3 and systemic sclerosis: Previous reports have described the existence of autoantibodies targeting muscarinic-3-acetylcholine receptors expressed on the smooth muscle cells in the GI tract in the sera of SSc patients with GI symptoms [12, 13], which demonstrate significant inhibition of muscarinic-3-acetylcholine receptors in vitro [14].